BioCentury | Mar 9, 2018
Clinical News

VBL's VB-111 misses in Phase III for glioblastoma

...TLR2) and TLR4 antagonist that inhibits production of proinflammatory cytokines IL-12 and IL-23. VBL granted NanoCarrier Co. Ltd....
...exclusive rights to develop and commercialize VB-111 in Japan (see BioCentury, Nov. 10, 2017 ). NanoCarrier Co. Ltd....
BioCentury | Mar 8, 2018
Clinical News

VBL falls on Phase III glioblastoma miss

...of Sept. 30, 2017, and received $15 million up front from its November deal with NanoCarrier Co. Ltd....
BioCentury | Jan 13, 2018
Finance

JPM jolt

...wk chg Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) € 42.28 63% Atara Biotherapeutics Inc. (NASDAQ:ATRA) $28.25 53% NanoCarrier Co. Ltd....
BioCentury | Jan 5, 2018
Clinical News

VBL begins Phase III of gene therapy VB-111 to treat ovarian cancer

...modified murine pre-proendothelin promoter (PPE-1-3x) developed using Vascular Targeting System (VTS) technology. Vascular Biogenics granted NanoCarrier Co. Ltd....
...obadenovec in Japan (see BioCentury, Nov. 10, 2017 ). Vascular Biogenics Ltd. (NASDAQ:VBLT), Modiin, Israel NanoCarrier Co. Ltd....
...and patient reported outcome measures Status: Phase III started Milestone: Phase III data (1Q18) Chris Lieu ofranergene obadenovec VB-111 NanoCarrier Co. Ltd. Vascular...
BioCentury | Nov 10, 2017
Company News

VBL grants NanoCarrier Japanese rights to GBM gene therapy VB-111

...Vascular Biogenics Ltd. (NASDAQ:VBLT) granted NanoCarrier Co. Ltd. (Tokyo:4571) exclusive rights to develop and commercialize ofranergene obadenovec (VB-111...
...inquiries. Vascular Biogenics Ltd. (NASDAQ:VBLT), Modiin, Israel NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Business: Cancer Jaime De Leon ofranergene obadenovec VB-111 VB-201 NanoCarrier Co. Ltd. Toll-like...
BioCentury | Nov 6, 2017
Company News

VBL grants NanoCarrier Japanese rights to GBM gene therapy

...Vascular Biogenics Ltd. (NASDAQ:VBLT) granted NanoCarrier Co. Ltd. (Tokyo:4571) exclusive rights to develop and commercialize ofranergene obadenovec (VB-111...
...17, 2015) . NanoCarrier gained Y18 to Y742 in Japan on Monday. Jaime De Leon cisplatin micelles Nanoplatin NC-6004 ofranergene obadenovec VB-111 VB-201 NanoCarrier Co. Ltd. Toll-like...
BioCentury | Mar 31, 2017
Company News

TPG Biologics, Nanocarrier deal

...to inquiries. TPG Biologics Inc. , Taipei, Taiwan NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Business: Drug delivery Alicia Parker NanoCarrier Co. Ltd. TPG...
BioCentury | Feb 17, 2017
Clinical News

NC-6300: Ph I data

...the contract had passed," but did not disclose when or whether that period has ended. NanoCarrier Co. Ltd....
...II dose, tumor response and pharmacokinetics Status: Phase I data Milestone: NA Julian Zhu Epirubicin Micelle K-912 NC-6300 Kowa Co. Ltd. NanoCarrier Co. Ltd....
BioCentury | Oct 31, 2016
Company News

NanoCarrier, Kowa deal

...deal to focus on development in the U.S. and Europe (see BioCentury, Oct. 10, 2011). NanoCarrier Co. Ltd....
BioCentury | Oct 3, 2016
Finance

Dressed in black

...M402) after it fails in a Phase I/II trial to treat advanced metastatic pancreatic cancer NanoCarrier Co. Ltd....
Items per page:
1 - 10 of 42
BioCentury | Mar 9, 2018
Clinical News

VBL's VB-111 misses in Phase III for glioblastoma

...TLR2) and TLR4 antagonist that inhibits production of proinflammatory cytokines IL-12 and IL-23. VBL granted NanoCarrier Co. Ltd....
...exclusive rights to develop and commercialize VB-111 in Japan (see BioCentury, Nov. 10, 2017 ). NanoCarrier Co. Ltd....
BioCentury | Mar 8, 2018
Clinical News

VBL falls on Phase III glioblastoma miss

...of Sept. 30, 2017, and received $15 million up front from its November deal with NanoCarrier Co. Ltd....
BioCentury | Jan 13, 2018
Finance

JPM jolt

...wk chg Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) € 42.28 63% Atara Biotherapeutics Inc. (NASDAQ:ATRA) $28.25 53% NanoCarrier Co. Ltd....
BioCentury | Jan 5, 2018
Clinical News

VBL begins Phase III of gene therapy VB-111 to treat ovarian cancer

...modified murine pre-proendothelin promoter (PPE-1-3x) developed using Vascular Targeting System (VTS) technology. Vascular Biogenics granted NanoCarrier Co. Ltd....
...obadenovec in Japan (see BioCentury, Nov. 10, 2017 ). Vascular Biogenics Ltd. (NASDAQ:VBLT), Modiin, Israel NanoCarrier Co. Ltd....
...and patient reported outcome measures Status: Phase III started Milestone: Phase III data (1Q18) Chris Lieu ofranergene obadenovec VB-111 NanoCarrier Co. Ltd. Vascular...
BioCentury | Nov 10, 2017
Company News

VBL grants NanoCarrier Japanese rights to GBM gene therapy VB-111

...Vascular Biogenics Ltd. (NASDAQ:VBLT) granted NanoCarrier Co. Ltd. (Tokyo:4571) exclusive rights to develop and commercialize ofranergene obadenovec (VB-111...
...inquiries. Vascular Biogenics Ltd. (NASDAQ:VBLT), Modiin, Israel NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Business: Cancer Jaime De Leon ofranergene obadenovec VB-111 VB-201 NanoCarrier Co. Ltd. Toll-like...
BioCentury | Nov 6, 2017
Company News

VBL grants NanoCarrier Japanese rights to GBM gene therapy

...Vascular Biogenics Ltd. (NASDAQ:VBLT) granted NanoCarrier Co. Ltd. (Tokyo:4571) exclusive rights to develop and commercialize ofranergene obadenovec (VB-111...
...17, 2015) . NanoCarrier gained Y18 to Y742 in Japan on Monday. Jaime De Leon cisplatin micelles Nanoplatin NC-6004 ofranergene obadenovec VB-111 VB-201 NanoCarrier Co. Ltd. Toll-like...
BioCentury | Mar 31, 2017
Company News

TPG Biologics, Nanocarrier deal

...to inquiries. TPG Biologics Inc. , Taipei, Taiwan NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Business: Drug delivery Alicia Parker NanoCarrier Co. Ltd. TPG...
BioCentury | Feb 17, 2017
Clinical News

NC-6300: Ph I data

...the contract had passed," but did not disclose when or whether that period has ended. NanoCarrier Co. Ltd....
...II dose, tumor response and pharmacokinetics Status: Phase I data Milestone: NA Julian Zhu Epirubicin Micelle K-912 NC-6300 Kowa Co. Ltd. NanoCarrier Co. Ltd....
BioCentury | Oct 31, 2016
Company News

NanoCarrier, Kowa deal

...deal to focus on development in the U.S. and Europe (see BioCentury, Oct. 10, 2011). NanoCarrier Co. Ltd....
BioCentury | Oct 3, 2016
Finance

Dressed in black

...M402) after it fails in a Phase I/II trial to treat advanced metastatic pancreatic cancer NanoCarrier Co. Ltd....
Items per page:
1 - 10 of 42